Responding to (DoD) RFPRecently Awarded a Department of Defense Contract, Cleveland BioLabs, Inc. (NASDAQ: CBLI), is Now Responding to a New Department of Defense RFP
The Company is well positioned from a competitive standpoint, as a current Contractor within the Department of Defense.
CBLI recently received a contract for over $1 million from the Defense Threat Reduction Agency (DTRA) to fund "development leading to the acquisition" of CBLB502, in collaboration with the Armed Forces Radiobiology Research Institute (AFRRI), which has also received significant independent funding for work on the Company's product compound.
Earlier this year, the Department of Defense issued an RFP for the acquisition of up to 500,000 doses of radiation antidote. CBLI believes that the two key features outlined in the RFP, protection of gastrointestinal tract and overall survival benefits; positions its lead compound ahead of any known competition. The RFP award, if successful, would provide funding for development through FDA approval, as well as a commitment to purchase, thereafter.